Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NORTH CHICAGO, Ill., April 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new data from its expansive neuroscience portfolio will be presented at the 2021 American Academy of Neurology (AAN) Annual Meeting, to be held virtually from April 17-22.

AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting

Bristol-Myers

Horizon Pharma

Seagen

Vertex Pharmaceuticals

Horizon Therapeutics has a clear path to significant sales growth.

Does 2021's Best Biopharma to Work for Belong in Your Portfolio?

Gilead Sciences

GlaxoSmithKline

Pfizer

Healthcare is one of the most defensive sectors and often contains strong moats. Fortunately for income investors, there are also numerous high-yield opportunities in the space.

4 High-Yield Healthcare Stocks That Could Richly Reward Investors

Shares of AbbVie have climbed more than 22% over the past 12 months, but there's still room to grow.

Should You Buy AbbVie in April?

The FDA extends the review period of AbbVie's (ABBV) label expansion application for Rinvoq in atopic dermatitis by three months.

AbbVie's (ABBV) Rinvoq Dermatitis sNDA Review Gets Delayed

The FDA has extended the review period for AbbVie Inc's (NYSE: ABBV) supplemental marketing application seeking upadacitinib approval to treat adults and adolescents with moderate to severe atopic dermatitis. The action date has been extended three months to early Q3 2021.

AbbVie's Upadacitinib US Application Review In Atopic Dermatitis Postponed

NORTH CHICAGO, Ill., April 2, 2021 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for upadacitinib in the treatment of adults and adolescents with moderate to severe atopic dermatitis.

AbbVie Announces Extension of Review for Supplemental New Drug Application of Upadacitinib for the Treatment of Moderate to Severe Atopic Dermatitis

TCG BDC

Canadian Natural Resources

Enbridge

Lockheed Martin

Medical Properties Trust

Merck

Realty Income Corp

OFS Capital

Sometimes, it may seem like growth and momentum investing is the way to go, but in the long run, a focus on value and income stocks is a winning strategy. Not all income stocks are necessarily attractive at a certain point - one should consider valuation before making an investment.

Top 10 Undervalued High-Yield Income Stocks For Q2

IRVINE, Calif., April 1, 2021 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of SkinMedica ® Neck Correct Cream, the first product from the professional-grade skincare line formulated to address the specific biology of the skin on the neck and décolleté area.

SkinMedica® Launches Neck Correct Cream for Neck and Décolleté

NORTH CHICAGO, Ill., April 1, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the New England Journal of Medicine has published 24-week results from the Phase 3 SELECT-PsA 1 trial evaluating RINVOQ ™  (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).1 These data build on previously announced Phase 3 topline results showing that upadacitinib 15 mg and 30 mg met the primary endpoint of ACR20 response at week 12 versus placebo as well as key secondary endpoints.1  "These data show upadacitinib's potential to improve clinical and radiographic outcomes for people with psoriatic arthritis, a complex and progressive autoimmune disease," said Thomas Hudson, MD, senior vice president, research and development, chief scientific officer, AbbVie.

New England Journal of Medicine Publishes 24-Week Results from Phase 3 Study Evaluating RINVOQ™ (upadacitinib) in Psoriatic Arthritis

AbbVie stock tumbled in mid-March after the Food and Drug Administration requested additional information before considering new approvals for its potential blockbuster drug, Rinvoq. The post Is It Time To Buy AbbVie Stock — Or Will Pfizer's Bad News Continue To Hurt?

Is It Time To Buy AbbVie Stock — Or Will Pfizer's Bad News Continue To Hurt?

AbbVie faces one of the toughest challenges in the pharmaceutical industry - the patent expiry of its $20bn-selling immunology drug Humira in 2023. Management provided detailed long-term revenue and financial guidance during its Feb earnings call illustrating how it will grow revenue long-term in spite of the LOE.

AbbVie: Plotting The Course To Revenue Growth Ex-Humira - The Bull Case

NORTH CHICAGO, Ill., March 31, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2021 financial results on Friday, April 30, 2021, before the market opens.

AbbVie to Host First-Quarter 2021 Earnings Conference Call

The Best Value Stock to Buy Right Now

ABBV can be a bit volatile for most income investors, though they carry almost a 5% yield at this time. The company is undervalued, probably being discounted due to the reliance on Humira.

Collecting AbbVie Premium, Ex-Date Coming Up For This ~5% Yielder

Innovative Industrial Properties

Scotts Miracle-Gro

Constellation Brands

Village Farms International

cbdMD Inc

You may be surprised that not all cannabis stocks are focused entirely on weed. Here are some diversified companies to consider.

7 Cannabis Stocks That Offer Much More Than Just Pot

The FDA has accepted for review AbbVie Inc's (NYSE: ABBV) marketing application seeking approval for Atogepant for the preventive treatment of migraine in adults who meet the criteria for episodic migraine. The regulatory decision is expected in late Q3 2021.

FDA Accepts AbbVie's Atogepant US Review Application For Migraine

NORTH CHICAGO, Ill., March 30, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for atogepant, an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), for the preventive treatment of migraine in adults who meet criteria for episodic migraine.

U.S. FDA Accepts AbbVie's New Drug Application for Atogepant for the Preventive Treatment of Migraine

Enterprise Products Partners

You don't have to sacrifice growth for great dividend yields with these stocks.

3 High-Yield Dividend Stocks With Solid Growth Prospects

Amgen

Johnson & Johnson

Eli Lilly

Sanofi

Pharmaceutical stocks with stable, substantial dividends can hold their own in almost any environment, making them ideal for long-term income investors.

7 Big Pharmaceutical Stocks for Bigger Income

Citigroup

Intel

MPLX

Prudential Financial

Simon Property Group

SPDR S&P 500 ETF Trust

AT&T

Vanguard Value ETF

Vanguard Growth ETF

W. P. Carey

At the end of 2020, we showcased a list of 10 undervalued income stocks for 2021. Looking back, we see that the performance, on average, has been great so far. In this report, we examine the reasons for that and will look at whether all 10 are still strong buys today.

Top 10 Undervalued Income Stocks For 2021 - Value Beats Growth

Cardinal Health

Chevron

Walgreens

With March almost over, many investors are looking to the second quarter and beyond.

5 High-Yielding Dividend Aristocrat Stocks Are Perfect Now for Worried Investors

Apple

Atmos Energy

General Electric

General Motors

JPMorgan Chase & Co

Microsoft

Value stocks aren't always a sure thing despite their reassuring metrics. These seven seem to be close to it though.

7 Value Stocks That Will Reward Investors Who Have Some Patience

The stock of AbbVie (NYSE:ABBV, 30-year Financials) appears to be fairly valued, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded.

AbbVie Stock Shows Every Sign Of Being Fairly Valued

News for AbbVie Stock (ABBV)